公开(公告)号：US11198690B2

公开(公告)日：2021-12-14

申请号：US16630120

申请日：2018-07-11

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Takaaki Matsubara ,  Hiroki Urabe ,  Ryo Suzuki ,  Aya Futamura ,  Ryo Kinoshita ,  Nobutaka Hattori ,  Hideaki Tabuse ,  Koreaki Imura ,  Norikazu Otake

IPC分类号： C07D413/14 ,  C07D265/06

摘要： Provided is a novel process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative.
More specifically, provided is a process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1): the process comprising reacting 3-aminopropan-1-ol with glyoxylic acid.

公开(公告)号：US20210070747A1

公开(公告)日：2021-03-11

申请号：US16496066

申请日：2018-03-23

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Hideaki AMADA ,  Norikazu OTAKE ,  Fumihito USHIYAMA ,  Chunhae KIM ,  Tomoki TAKEUCHI ,  Nozomi TANAKA

IPC分类号： C07D417/14 ,  C07D215/227 ,  C07D417/12 ,  C07D401/12

摘要： Provided are: useful novel compounds that exhibit antibacterial activity based on their actions for inhibiting GyrB of DNA gyrase and ParE of topoisomerase IV; and 2(1H)-quinolinone derivatives represented by formula [1]: or pharmaceutically acceptable salts thereof.

公开(公告)号：US20210059984A1

公开(公告)日：2021-03-04

申请号：US16556948

申请日：2019-08-30

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Fan FAN ,  Richard J. ROMAN ,  Shaoxun WANG

IPC分类号： A61K31/382 ,  A61P25/28 ,  A61P3/06

摘要： A new drug useful in the treatment of cognitive impairment is provided, in which an effective amount of luseogliflozin or a pharmaceutically acceptable salt thereof, or a hydrate of luseogliflozin or the salt is contained as an active ingredient.

公开(公告)号：US20210040062A1

公开(公告)日：2021-02-11

申请号：US16077798

申请日：2017-02-14

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Hiroaki TANAKA ,  Ayako BOHNO

IPC分类号： C07D401/04

摘要： The present invention provides a compound represented by formula [I′] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula —O—CH2CH2—; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

公开(公告)号：US20180282252A1

公开(公告)日：2018-10-04

申请号：US15764598

申请日：2016-09-29

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Norikazu OTAKE ,  Daisuke MATSUDA ,  Rie SHIMONO ,  Hideaki TABUSE ,  Minoru MORIYA ,  Yohei KOBASHI ,  Yohei MATSUDA ,  Tomokazu TAMAOKI

IPC分类号： C07C51/09 ,  C07C67/343 ,  B01J27/10 ,  B01J31/02

CPC分类号： C07C51/09 ,  B01J27/10 ,  B01J31/0244 ,  C07B53/00 ,  C07B61/00 ,  C07B2200/07 ,  C07C57/58 ,  C07C67/343 ,  C07C69/65

摘要： A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10022389B2

公开(公告)日：2018-07-17

申请号：US14765134

申请日：2014-02-03

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Daisuke Yamamoto ,  Fusayo Io ,  Koji Yamamoto

IPC分类号： A61K31/7034 ,  A61K31/351 ,  C07D309/10 ,  A61K9/16 ,  A61K9/20

摘要： New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:

公开(公告)号：US20170267708A1

公开(公告)日：2017-09-21

申请号：US15504946

申请日：2015-08-17

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Tomohiro SUGIMOTO ,  Masato HAYASHI ,  Takanori KAWAGUCHI

IPC分类号： C07H17/08

CPC分类号： C07H17/08

摘要： A useful novel compound that shows superior antibacterial activity also against erythromycin resistant bacteria, for example, resistant pneumococci, streptococci, mycoplasmas, and the like, against which sufficient antibacterial activity cannot be obtained with conventional macrolide antibiotics, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof.

公开(公告)号：US09522914B2

公开(公告)日：2016-12-20

申请号：US14353447

申请日：2012-10-25

申请人： TAISHO PHARMACEUTICAL CO., LTD

发明人： Mitsukane Yoshinaga ,  Takeshi Kuwada ,  Naoki Miyakoshi ,  Tomoko Ishizaka ,  Daisuke Wakasugi ,  Shin-ichi Shirokawa ,  Nobutaka Hattori ,  Youichi Shimazaki

IPC分类号： C07D491/107 ,  C07D471/08 ,  C07D403/10 ,  C07D498/08 ,  C07D233/64 ,  C07D401/10 ,  C07D231/12 ,  C07D233/70 ,  C07D233/90 ,  C07D401/04 ,  C07D403/04 ,  C07D403/06 ,  C07D413/10 ,  C07D249/08 ,  C07D451/06 ,  C07D249/10 ,  C07D249/12 ,  C07D263/32 ,  C07D277/20 ,  C07D277/30 ,  C07D207/444

CPC分类号： C07D471/08 ,  C07D207/444 ,  C07D231/12 ,  C07D233/64 ,  C07D233/70 ,  C07D233/90 ,  C07D249/08 ,  C07D249/10 ,  C07D249/12 ,  C07D263/32 ,  C07D277/20 ,  C07D277/30 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D413/10 ,  C07D451/06 ,  C07D491/107 ,  C07D498/08

摘要： The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor:

公开(公告)号：US20160289208A1

公开(公告)日：2016-10-06

申请号：US14442157

申请日：2013-11-12

申请人： TAISHO PHARMACEUTICAL CO., LTD. ,  NISSAN CHEMICAL INDUSTRIES, LTD.

发明人： Shoichi KURODA ,  Yudai IMAI ,  Takanori KAWAGUCHI ,  Keiko FUSEGI ,  Masahiro BOHNO ,  Hajime ASANUMA ,  Tomomichi CHONAN ,  Nagaaki SATO ,  Souichi MONMA ,  Shigetada SASAKO ,  Marie MIZUTANI ,  Shin ITOH ,  Takumi OKADA ,  Hirofumi OTA ,  Seishi ISHIYAMA

IPC分类号： C07D401/06

CPC分类号： C07D401/06 ,  A61K31/4439

摘要： This 2-pyridone compound represented by formula [1] or a tautomer of said compound, or a pharmaceutically acceptable salt of said compound or said tautomer, or a solvate of said compound or the like has a superior UK-activating effect and is useful as a pharmaceutical.

摘要翻译： 由式[1]表示的2-吡啶酮化合物或所述化合物的互变异构体或所述化合物或所述互变异构体的药学上可接受的盐或所述化合物等的溶剂合物具有优异的GK-活化作用，可用作 制药。

公开(公告)号：US20150327585A1

公开(公告)日：2015-11-19

申请号：US14652503

申请日：2013-12-12

申请人： TAISHO PHARMACEUTICAL CO., LTD.

发明人： Takashi DOMOTO ,  Marie YAMAJI ,  Akane SAKATA

IPC分类号： A23L1/29 ,  A23L2/54 ,  A61K9/00 ,  A23L1/0524 ,  A23L1/0526 ,  A61K47/36 ,  A23L2/38 ,  A23L2/68

CPC分类号： A23L2/68 ,  A23L2/38 ,  A23L2/40 ,  A23L2/52 ,  A23L2/54 ,  A23L29/231 ,  A23L29/238 ,  A23L29/256 ,  A23L29/272 ,  A23L33/20 ,  A23V2002/00 ,  A61K9/0095 ,  A61K47/36

摘要： An aqueous carbonated beverage comprises any one of: 0.01 w/v % or more of a LM pectin; 0.1 w/v % or more of alginic acid or a salt thereof; and 0.001 w/v % or more of gellan gum, wherein the aqueous carbonated beverage has a pH of 3.5 to 7.0.

摘要翻译： 含水碳酸饮料包含：0.01w / v％以上的LM果胶中的任一种; 0.1w / v％以上的藻酸或其盐; 和0.001w / v％以上的结冷胶，其中所述碳酸饮料的pH为3.5〜7.0。